One team. Three lenses. One answer.

Angeliki is a physician‑scientist and molecular pathologist with more than three decades in medicine and science, nineteen of them at Pfizer, where she chaired benefit‑risk decisions and held final medical judgement on the company's medicines.

She graduated in medicine from Democritus University of Thrace and completed her pathology residency and PhD in molecular pathology at Aristotle University of Thessaloniki, with further training in Switzerland and the United States.

Hedley argues that drug availability is national infrastructure, not a procurement problem. He is the author of Transforming the Pharmaceutical Supply Chain (Wiley, 2025), a board‑level guide that reframes supply‑chain design as a strategic capability, drawing on lessons from aerospace, semiconductors and other high‑reliability sectors.

His career began in 1979 at Miles Laboratories. He has since advised global pharma, biotechs, CDMOs and logistics leaders, including Lonza, Catalent, Oxford BioMedica, Tower Cold Chain, Marken and UPS Healthcare, on advanced manufacturing supply‑chain bids, footprint strategy and resilience programmes.

He regularly briefs boards, non‑executives and policymakers, and provides independent expert opinion to legal teams on cases where supply‑chain and manufacturing failures are alleged to have caused patient harm.

A seasoned leader in healthcare supply chain management, grounded in a strong background in executive leadership. Niels specialises in modernising healthcare supply chains through end‑to‑end planning, AI technology and patient‑centric solutions.